QQ客服 官方微博 反馈留言

	First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm plus ) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs).
	Hirsh, Vera; Yang, James Chih-Hsin; Tan, Eng-Huat; O'Byrne, Ken; Zhang, Li; Boyer, Michael J.; Mok, Tony; Lee, Ki Hyeong; Lu, Shun; Shi, Yuankai
	2016
卷号	34期号:15
ISSN号	0732-183X
DOI	10.1200/JCO.2016.34.15_suppl.9046
URL标识	查看原文
收录类别	SCIE
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6384897
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Hirsh, Vera,Yang, James Chih-Hsin,Tan, Eng-Huat,et al. First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm plus ) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs).[J],2016,34(15).
APA	Hirsh, Vera.,Yang, James Chih-Hsin.,Tan, Eng-Huat.,O'Byrne, Ken.,Zhang, Li.,...&Park, Keunchil.(2016).First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm plus ) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs)..,34(15).
MLA	Hirsh, Vera,et al."First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm plus ) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs).".34.15(2016).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。